Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nicardipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicardipine SCHEMBL31059901 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL34279 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL29430153 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL34277 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL1172950 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL1653198 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL29465066 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL41846 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL41845 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| Nicardipine SCHEMBL28750837 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34219 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0196841-A1 | N,N-dialkylguanidino dipeptides | SYNTEX (U.S.A.) INC. (US) | 1986-10-08 | — | — | EP | claimed |
| CN-85109017-A | The preparation technology of different dihydropyridine mixture and the purposes aspect medical thereof | — | 1986-08-27 | — | — | CN | claimed |
| US-4584294-A | Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents | MERCK & CO., INC. (US) | 1986-04-22 | — | — | US | claimed |
| US-4565823-A | NICARDIPINE, ANTILIPEMIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-01-21 | — | — | US | claimed |
| EP-0166353-A2 | Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0149475-A2 | Medicaments for the treatment and prevention of liver damage | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-07-24 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4343789-A | NICARDIPINE AND POLYOXYETHYLENE GLYCOL | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1982-08-10 | — | — | US | claimed |